title: Dissecting the PI3K Signaling Axis in Pediatric Solid Tumors: Novel Targets for Clinical Integration.
abstract: Children with solid tumors represent a unique population. Recent improvements in pediatric solid tumor survival rates have been confined to low- and moderate-risk cancers, whereas minimal to no notable improvement in survival have been observed in high-risk and advanced-stage childhood tumors. Treatments for patients with advanced disease are rarely curative, and responses to therapy are often followed by relapse, which highlights the large unmet need for novel therapies. Recent advances in cancer treatment have focused on personalized therapy, whereby patients are treated with agents that best target the molecular drivers of their disease. Thus, a better understanding of the pathways that drive cancer or drug resistance is of critical importance. One such example is the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway, which is activated in many solid cancer patients and represents a target for therapy. PI3K/Akt/mTOR pathway activation has also been observed in tumors resistant to agents targeting upstream receptor tyrosine kinases (RTKs). Agents that target this pathway have the potential to shut down survival pathways, and are being explored both in the setting of pathway-activating mutations and for their ability to restore sensitivity to upstream signaling targeted agents. Here, we examine the role of the PI3K/Akt/mTOR pathway in pediatric solid tumors, review the novel agents being explored to target this pathway, and explore the potential role of the inhibition of this pathway in the clinical development of these agents in children.
authors: Department of Surgery, St. Jude Children's Research Hospital Memphis, TN, USA.
authors: Amos H P
authors: AH
authors: Loh
authors: Rachel C
authors: RC
authors: Brennan
authors: Walter H
authors: WH
authors: Lang
authors: Robert J
authors: RJ
authors: Hickey
authors: Linda H
authors: LH
authors: Malkas
authors: John A
authors: JA
authors: Sandoval
keywords: Akt; PI3K; mTOR; pediatric solid tumors
references: Int J Cancer. 2013 Aug 15;133(4):997-1005
references: 23382028
references: Cancer Res. 1993 Nov 1;53(21):5108-12
references: 8221646
references: Paediatr Drugs. 2012 Oct 1;14(5):299-316
references: 22845486
references: Science. 1993 Mar 5;259(5100):1450-3
references: 8383879
references: Int J Cancer. 2008 Jan 15;122(2):433-43
references: 17935137
references: Pediatr Blood Cancer. 2010 Jul 1;54(7):1035-7
references: 20108343
references: Pol J Pathol. 2010;61(4):192-8
references: 21290341
references: Oncogene. 2008 May 1;27(20):2910-22
references: 18026138
references: Carcinogenesis. 2008 Nov;29(11):2062-72
references: 18687666
references: Expert Opin Drug Metab Toxicol. 2012 May;8(5):623-33
references: 22512706
references: J Clin Oncol. 2007 Oct 20;25(30):4806-12
references: 17947729
references: Cancer. 2011 Dec 1;117(23):5412-22
references: 21590687
references: Cancer Res. 2010 Dec 15;70(24):10329-39
references: 20971812
references: Cancer Lett. 2007 Aug 18;253(2):215-23
references: 17350164
references: Toxicol Appl Pharmacol. 2012 Mar 15;259(3):402-10
references: 22326785
references: Mol Cancer Ther. 2011 Nov;10(11):2016
references: 22072802
references: Lancet. 1989 Jul 22;2(8656):227
references: 2568561
references: J Clin Oncol. 2010 Mar 1;28(7):1168-74
references: 20124186
references: Clin Transl Oncol. 2012 Mar;14(3):197-206
references: 22374423
references: J Antibiot (Tokyo). 1975 Oct;28(10):727-32
references: 1102509
references: Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7421-6
references: 10377430
references: Target Oncol. 2011 Jun;6(2):119-24
references: 21533544
references: Nat Rev Cancer. 2009 Aug;9(8):550-62
references: 19629070
references: Cell Signal. 2000 Dec;12(11-12):751-7
references: 11152961
references: J Biol Chem. 1997 Dec 5;272(49):30822-7
references: 9388225
references: Clin Cancer Res. 2011 Sep 15;17(18):6052-60
references: 21750201
references: Cancer. 2008 Sep 15;113(6):1453-61
references: 18704985
references: Cell Cycle. 2009 May 1;8(9):1352-8
references: 19305151
references: Biochim Biophys Acta. 2008 Jan;1784(1):150-8
references: 17964232
references: Ann Surg. 2005 May;241(5):684-91; discussion 691-2
references: 15849504
references: Cell. 1999 Mar 19;96(6):857-68
references: 10102273
references: BMC Cancer. 2006 Jul 05;6:177
references: 16822308
references: Cancer. 2007 Jun 1;109(11):2257-67
references: 17440983
references: Clin Cancer Res. 2012 Jan 1;18(1):184-95
references: 22065080
references: Mol Cell Biol. 1997 Mar;17(3):1595-606
references: 9032287
references: Genes Chromosomes Cancer. 2004 Jan;39(1):11-21
references: 14603437
references: Nat Rev Drug Discov. 2005 Dec;4(12):988-1004
references: 16341064
references: Cell Growth Differ. 1995 Mar;6(3):263-9
references: 7794794
references: Br J Cancer. 2010 Jul 27;103(3):370-81
references: 20606682
references: Cancer Res. 2004 Sep 1;64(17):6026-34
references: 15342383
references: Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22299-304
references: 20007781
references: Int J Cancer. 2004 Jan 20;108(3):358-66
references: 14648701
references: Oncogene. 2008 Aug 28;27(37):4998-5010
references: 18504440
references: J Biol Chem. 1996 Aug 9;271(32):19146-51
references: 8702591
references: Cancer Res. 2007 Jan 15;67(2):735-45
references: 17234785
references: J Clin Oncol. 2011 Jul 20;29(21):2933-40
references: 21690471
references: BMC Cancer. 2004 Aug 07;4:45
references: 15298715
references: Eur J Cancer. 2012 Jan;48(2):253-62
references: 22033322
references: J Clin Oncol. 2012 Jan 20;30(3):282-90
references: 22162589
references: J Natl Cancer Inst. 2010 Jun 2;102(11):758-70
references: 20463309
references: Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2077-81
references: 10051597
references: J Clin Oncol. 2000 Jan;18(1):204-13
references: 10623711
references: Cancer Lett. 2006 Sep 28;241(2):184-96
references: 16412571
references: J Biol Chem. 1997 Jan 3;272(1):154-61
references: 8995241
references: Ann Clin Lab Sci. 2007 Spring;37(2):141-7
references: 17522369
references: Clin Cancer Res. 2009 Feb 15;15(4):1428-34
references: 19228743
references: Asian Pac J Cancer Prev. 2012;13(7):3103-7
references: 22994717
references: Curr Pharm Des. 2010 Jan;16(1):34-44
references: 20214616
references: Cell Signal. 2008 Apr;20(4):659-65
references: 18207367
references: Cancer Res. 2008 Oct 1;68(19):8022-30
references: 18829560
references: Cancer Res. 1999 Nov 15;59(22):5745-50
references: 10582694
references: Curr Opin Oncol. 2006 Jan;18(1):77-82
references: 16357568
references: J Cancer Res Clin Oncol. 2009 Aug;135(8):1125-36
references: 19205734
references: Br J Pharmacol. 2005 Nov;146(5):633-41
references: 16100524
references: Front Oncol. 2013 Feb 04;3:9
references: 23383402
references: J Biol Chem. 2001 Sep 21;276(38):35622-8
references: 11468290
references: Growth Horm IGF Res. 2001 Oct;11(5):289-97
references: 11735247
references: Mol Cancer Ther. 2008 Jul;7(7):1851-63
references: 18606717
references: Neoplasia. 2005 Nov;7(11):967-76
references: 16331882
references: Br J Cancer. 2005 Feb 28;92(4):705-10
references: 15685229
references: Cancer. 2012 Jun 1;118(11):2905-14
references: 22006429
references: Int J Cancer. 2004 May 1;109(5):673-9
references: 14999773
references: N Engl J Med. 2010 Nov 4;363(19):1801-11
references: 21047224
references: Mod Pathol. 2007 Sep;20(9):936-46
references: 17585318
references: Blood. 2012 Sep 27;120(13):2679-89
references: 22826565
references: Clin Cancer Res. 2012 Jul 1;18(13):3603-15
references: 22550167